Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN D VICUNA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1275755670
CMS profile
148305
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$12,155.54

74 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN D VICUNA

NPI 1275755670 · CMS profile ID 148305

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275755670?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275755670?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275755670?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRIAN D VICUNA, NPI 1275755670, CMS profile ID 148305, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–74 of 74 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1275755670?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

74 matching records · $12,155.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 74 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–74 of 74.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $19.6204/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744219241 CMS
Novartis Pharmaceuticals Corporation $61.4704/17/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726172269 CMS
Novartis Pharmaceuticals Corporation $61.4703/16/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726172267 CMS
Agios Pharmaceuticals, Inc. $18.0803/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751963515 CMS
AstraZeneca Pharmaceuticals LP $19.8103/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736287503 CMS
Blueprint Medicines Corporation $28.0903/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750714899 CMS
Novartis Pharmaceuticals Corporation $14.1003/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173803 CMS
Novartis Pharmaceuticals Corporation $14.5602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173799 CMS
Janssen Biotech, Inc. $20.4302/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719061359 CMS
Daiichi Sankyo Inc. $65.6802/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739483705 CMS
Lilly USA, LLC $23.3402/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728380513 CMS
Novartis Pharmaceuticals Corporation $61.4702/16/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173915 CMS
Novartis Pharmaceuticals Corporation $24.2302/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173797 CMS
Alexion Pharmaceuticals, Inc. $11.4702/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726627827 CMS
Dendreon Pharmaceuticals LLC $16.3202/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749840937 CMS
GlaxoSmithKline, LLC. $24.6102/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738505985 CMS
Daiichi Sankyo Inc. $20.3602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739482963 CMS
AstraZeneca Pharmaceuticals LP $16.4501/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736051829 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.6901/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713621567 CMS
Amgen Inc. $12.6401/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740940235 CMS
Astellas Pharma US Inc $12.1501/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718394023 CMS
Novartis Pharmaceuticals Corporation $61.4701/15/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173805 CMS
Novartis Pharmaceuticals Corporation $61.4701/15/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726173913 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.5801/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713634989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,601.46 102
PY2020 $12,155.54 74
PY2021 $22,220.24 100
PY2022 $23,827.02 106
PY2023 $9,439.46 161
PY2024 $20,699.23 183
PY2025 $15,428.49 172

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $65,352.83 64
PY2024 Recipient $288.58 1
PY2024 Principal investigator $132,363.23 64
PY2023 Principal investigator $212,383.75 43
PY2022 Principal investigator $211,645.28 56
PY2021 Recipient $717.51 1
PY2021 Principal investigator $318,946.14 44
PY2020 Principal investigator $79,072.03 17
PY2019 Principal investigator $145,014.56 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211590336
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187243
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187247
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187252
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187256
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187260
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187265
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192187269
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188062
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188066
Principal investigator 1 GlaxoSmithKline, LLC. $601.00 10/31/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY MEOZ
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192188071
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182741
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182743
Principal investigator 1 Astellas Pharma Global Development $558.60 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182745
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182747
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182749
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182751
Principal investigator 1 Astellas Pharma Global Development $658.35 08/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182753
Principal investigator 1 Genentech, Inc. $2,500.00 08/26/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211590328
Principal investigator 1 Exelixis Inc. $6,030.00 08/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386564
Principal investigator 1 Genentech, Inc. $200.00 08/01/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211590324
Principal investigator 1 Exelixis Inc. $200.00 07/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222386550
Principal investigator 1 Genentech, Inc. $200.00 07/02/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA ALLISON CURTIS KINGSLEY MEOZ MICHAEL + SANCHEZ PROF CORP
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211590332
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182671
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182673
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182675
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182677
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182679
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182681
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182683
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182685
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182687
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182689
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182691
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182693
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182695
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182697
Principal investigator 1 Astellas Pharma Global Development $1,500.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182699
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182701
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182703
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182705
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182707
Principal investigator 1 Astellas Pharma Global Development $175.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182709
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182711
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182713
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182715
Principal investigator 1 Astellas Pharma Global Development $450.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182717
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182719
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182721
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182723
Principal investigator 1 Astellas Pharma Global Development $150.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182725
Principal investigator 1 Astellas Pharma Global Development $750.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182727
Principal investigator 1 Astellas Pharma Global Development $600.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182729
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182731
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182733
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182735
Principal investigator 1 Astellas Pharma Global Development $350.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182737
Principal investigator 1 Astellas Pharma Global Development $75.00 06/25/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234182739
Principal investigator 1 Ipsen Bioscience Inc. $24,665.13 04/08/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545753
Principal investigator 1 Genentech, Inc. $454.00 04/02/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211675721
Principal investigator 1 Genentech, Inc. $1,567.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL No dispute reported 06/30/2026 1211675724
Principal investigator 1 Ipsen Bioscience Inc. $650.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545747
Principal investigator 1 Ipsen Bioscience Inc. $200.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545749
Principal investigator 1 Ipsen Bioscience Inc. $200.00 01/27/2025 Non-covered Recipient Entity
Comprehensive Cancer Centers Of Nevada
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545751